Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
NCT01742299
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
155
Enrollment
INDUSTRY
Sponsor class
Conditions
GIST and CML
Interventions
DRUG:
imatinib mesylate
Sponsor
Novartis Pharmaceuticals